Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from TScan Therapeutics ( (TCRX) ) is now available.
TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, securing up to $52.5 million to refinance existing debt and fund corporate purposes. This non-dilutive financing extends the loan maturity to 2029, enhances TScan’s financial flexibility, and supports its ongoing development efforts in advancing cancer therapies, potentially benefiting patients and investors.
More about TScan Therapeutics
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for treating cancer patients. The company’s lead therapy candidates target hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation and aim to provide multiplex TCR-T therapies for various cancers through its ImmunoBank repository.
YTD Price Performance: -49.06%
Average Trading Volume: 314,861
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $158.5M
See more insights into TCRX stock on TipRanks’ Stock Analysis page.
